Nice approves Roche drug
NICE, the NHS rationing agency, has recommended Roche’s drug MabThera for use with more chemotherapy regimens. The National Institute for Health and Clinical Excellence (NICE), which decides if drugs are cost effective for NHS use, had already recommended MabThera in combination with CVP, the most common chemotherapy treatment for the incurable disease. Today it said the drug could be used with three more.